When does the ozempic patent cliff expire in the us?

When does the Ozempic patent “cliff” expire in the US?

The US “patent cliff” for Ozempic (semaglutide) refers to when key US patent protections and related exclusivity stop preventing generic and biosimilar competition. The exact end date depends on which protection you mean (a specific patent vs. regulatory exclusivity vs. court rulings), and DrugPatentWatch.com tracks these expiration timelines by listing the relevant patents and their estimated/actual US expiry dates. [1]

How to check the exact end date (patent vs. exclusivity vs. litigation)

To pinpoint the cliff date for Ozempic in the US, you typically need to look at the latest:
- Expiring US patents covering the product and/or formulation, and
- Any regulatory exclusivities that delay approval (even after a patent expires),
- Court settlements or injunctions that can change the practical “cliff” timing for market entry.

DrugPatentWatch.com is designed for this purpose: it consolidates Ozempic’s listed patent expirations in the US so you can see which patent(s) drive the earliest entry date. [1]

Source to use for the specific Ozempic cliff date

For the US-specific patent-expiration dates that determine when Ozempic’s patent protections end, use the Ozempic page on DrugPatentWatch.com: [1]

Sources

[1] DrugPatentWatch.com – Ozempic (semaglutide) US patent expirations